Literature DB >> 28593114

Transient Exacerbation of Nasal Symptoms following Endoscopic Transsphenoidal Surgery for Pituitary Tumors: A Prospective Study.

Benjamin M Davies1, Erica Tirr1, Yi Yuen Wang1,2, Kanna K Gnanalingham1,3.   

Abstract

Object  Endoscopic transsphenoidal surgery is the commonest approach to pituitary tumors. One disadvantage of this approach is the development of early postoperative nasal symptoms. Our aim was to clarify the peak onset of these symptoms and their temporal evolution. Methods  The General Nasal Patient Inventory (GNPI) was administered to 56 patients undergoing endoscopic transsphenoidal surgery for pituitary tumors preoperatively and at 1 day, 3 days, 2 weeks, 3 months, and 6 to 12 months postoperatively. Most patients underwent surgery for pituitary adenomas ( N  = 49; 88%) and through a uninostril approach ( N  = 55; 98%). Total GNPI (0-135) and scores for the 45 individual components were compared. Results  GNPI scores peaked at 1 to 3 days postoperatively, with rapid reduction to baseline by 2 weeks and below baseline by 6 to 12 months postsurgery ( p  < 0.01). Of the 45 individual symptoms on the GNPI scale, 19 (42%) worsened transiently after surgery ( p  < 0.05). Functioning tumors had a higher GNPI scores at postoperative day 1 and 3 than nonfunctioning tumors, although their temporal evolution was the same ( p  < 0.05). Conclusions  Nasal morbidity following endoscopic transsphenoidal pituitary surgery is common, but transient, more so in the functioning subgroup. Nasal symptoms improve below baseline by 6 to 12 months, without the need for specific long-term postoperative interventions in the vast majority of patients.

Entities:  

Keywords:  GNPI; adenoma; endoscopic; nasal symptoms; pituitary tumor; transsphenoidal

Year:  2017        PMID: 28593114      PMCID: PMC5461159          DOI: 10.1055/s-0036-1597814

Source DB:  PubMed          Journal:  J Neurol Surg B Skull Base        ISSN: 2193-634X


  21 in total

Review 1.  Early postoperative care following endoscopic sinus surgery: an evidence-based review with recommendations.

Authors:  Luke Rudmik; Zachary M Soler; Richard R Orlandi; Michael G Stewart; Neil Bhattacharyya; David W Kennedy; Timothy L Smith
Journal:  Int Forum Allergy Rhinol       Date:  2011-10-29       Impact factor: 3.858

2.  Predictors of sinonasal quality of life and nasal morbidity after fully endoscopic transsphenoidal surgery.

Authors:  Andrew S Little; Daniel Kelly; John Milligan; Chester Griffiths; Daniel M Prevedello; Ricardo L Carrau; Gail Rosseau; Garni Barkhoudarian; Bradley A Otto; Heidi Jahnke; Charlene Chaloner; Kathryn L Jelinek; Kristina Chapple; William L White
Journal:  J Neurosurg       Date:  2015-04-03       Impact factor: 5.115

Review 3.  Endoscopic transnasal approach to the pituitary--operative technique and nuances.

Authors:  Zsolt Zador; Kanna Gnanalingham
Journal:  Br J Neurosurg       Date:  2013-05-30       Impact factor: 1.596

4.  Improvements in site-specific quality of life 6 months after endoscopic anterior skull base surgery: a prospective study.

Authors:  Edward D McCoul; Vijay K Anand; Theodore H Schwartz
Journal:  J Neurosurg       Date:  2012-07-20       Impact factor: 5.115

5.  Quality-of-Life after Anterior Skull Base Surgery: A Systematic Review.

Authors:  Matthew A Kirkman; Anouk Borg; Alaa Al-Mousa; Nikolaos Haliasos; David Choi
Journal:  J Neurol Surg B Skull Base       Date:  2013-12-11

6.  Effects of steroids and retinoids on wound healing.

Authors:  C Wicke; B Halliday; D Allen; N S Roche; H Scheuenstuhl; M M Spencer; A B Roberts; T K Hunt
Journal:  Arch Surg       Date:  2000-11

7.  The development of a General Nasal Patient Inventory.

Authors:  S A Douglas; A H Marshall; D Walshaw; A K Robson; J A Wilson
Journal:  Clin Otolaryngol Allied Sci       Date:  2001-10

8.  Nasal morbidity following endoscopic skull base surgery: a prospective cohort study.

Authors:  John R de Almeida; Carl H Snyderman; Paul A Gardner; Ricardo L Carrau; Allan D Vescan
Journal:  Head Neck       Date:  2010-09-07       Impact factor: 3.147

9.  Endonasal transsphenoidal surgery: the patient's perspective-survey results from 259 patients.

Authors:  Joshua R Dusick; Felice Esposito; Carlos A Mattozo; Charlene Chaloner; David L McArthur; Daniel F Kelly
Journal:  Surg Neurol       Date:  2006-04

10.  Comparative inpatient resource utilization for patients undergoing endoscopic or microscopic transsphenoidal surgery for pituitary lesions.

Authors:  Andrew S Little; Kristina Chapple; Heidi Jahnke; William L White
Journal:  J Neurosurg       Date:  2014-04-11       Impact factor: 5.115

View more
  4 in total

1.  Impact of patient-reported nasal symptoms on quality of life after endoscopic pituitary surgery: a prospective cohort study.

Authors:  Wouter R van Furth; Amir H Zamanipoor Najafabadi; Merel van der Meulen; Marco J T Verstegen; Daniel J Lobatto; Maarten C Kleijwegt; Alberto M Pereira; Nienke R Biermasz
Journal:  Pituitary       Date:  2022-01-10       Impact factor: 4.107

2.  Sinonasal Quality of Life Outcomes after Endoscopic Endonasal Transsphenoidal Surgery with Posterior Septum Free Mucosal Graft Reconstruction.

Authors:  Tara J Wu; Angela Chen; Christine Wells; Anthony P Heaney; Marvin Bergsneider; Marilene B Wang
Journal:  J Neurol Surg B Skull Base       Date:  2020-09-10

3.  Equivalent outcomes in nasal symptoms following microscopic or endoscopic transsphenoidal surgery: results from multi-centre, prospective study.

Authors:  Charlie Osborne; Daniel Lewis; Ben Dixon; Carmela Caputo; Alison Magee; Kanna Gnanalingham; Yi Yuen Wang
Journal:  Acta Neurochir (Wien)       Date:  2022-02-08       Impact factor: 2.816

4.  A patient-reported outcome measure for patients with pituitary adenoma undergoing transsphenoidal surgery.

Authors:  Stephanie E Baldeweg; Hani Joseph Marcus; Elika Karvandi; John Gerrard Hanrahan; Danyal Zaman Khan; Pierre-Marc Boloux; Fion Bremner; Ivan Cabrilo; Neil Dorward; Joan Grieve; Sue Jackson; Glenda Jimenez; Inma Serrano; Victoria Anne Nowak; Angelos Kolias
Journal:  Pituitary       Date:  2022-07-15       Impact factor: 3.599

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.